Regeneron Pharmaceuticals Inc. Reports Strong Clinical Progress and Positive Market Response
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced a series of encouraging developments that reinforce its position in the biopharmaceutical sector. On 8 November 2025, the company disclosed detailed Phase 2 data for two investigational factor XI (FXI) antibodies—REGN7508Cat and REGN9933A2—designed to prevent venous thromboembolism (VTE) in patients undergoing total knee replacement surgery. The results, presented at the American Heart Association Scientific Sessions and published in The Lancet, showed a significant reduction in VTE events compared with standard anticoagulation therapy. In the ROXI‑VTE‑I study, REGN9933A2 achieved a 12.4 % VTE rate versus 22.2 % with apixaban and 17.2 % with enoxaparin. The ROXI‑VTE‑II study demonstrated that REGN7508Cat reduced VTE incidence to 7.1 % versus 17.2 % with enoxaparin and 12.4 % with apixaban. A pooled analysis further confirmed the antithrombotic advantage of both agents over conventional therapy.
In parallel, Regeneron’s partnership with Sanofi on Dupixent (dupilumab) reached a milestone. The pivotal LIBERTY‑AFRS‑AIMS Phase 3 study, targeting allergic fungal rhinosinusitis (AFRS), met its primary endpoint and all secondary endpoints, leading to the acceptance of a supplemental Biologics License Application (sBLA) for FDA priority review. This development underscores Dupixent’s expanding therapeutic portfolio beyond its established indications in atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
Regeneron’s financial performance in Ireland was also highlighted. “Pillar Two” corporate tax reforms generated an additional €86 million in tax revenue for Regeneron Ireland DAC, reflecting a 56 % increase in pre‑tax profits from $1.47 billion to $4.09 billion. Revenues grew 8 % year‑on‑year, underscoring the company’s robust commercial operations in the European market.
The market reacted positively to these updates. UBS lifted its price target for Regeneron to $660, citing the drug pipeline’s depth and the company’s solid earnings profile. As of 6 November 2025, Regeneron’s stock closed at $657.53, approaching its 52‑week high of $834.42, with a market capitalization of approximately $66.4 billion and a price‑earnings ratio of 15.63.
Collectively, these clinical successes, regulatory advancements, and favorable fiscal outcomes reinforce Regeneron’s trajectory as a leading biopharmaceutical innovator, poised to capitalize on emerging therapeutic opportunities while maintaining a resilient financial footing.
